Biocardia ( (BCDA) ) has released its Q3 earnings. Here is a breakdown of the information Biocardia presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioCardia, Inc., based in Sunnyvale, California, is a biotechnology company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, utilizing its proprietary biotherapeutic delivery platforms.
In the third quarter of 2025, BioCardia reported significant progress in its clinical trials and financial results. The company secured $6 million in financing to support its CardiAMP cell therapy and Helix Transendocardial Delivery Catheter initiatives, with ongoing trials and regulatory submissions in the pipeline.
Key highlights include the CardiAMP cell therapy for heart failure, which showed promising results in completed trials and is currently enrolling for a phase 3 trial. The company also reported positive outcomes from its CardiAMP therapy for chronic myocardial ischemia, with patients experiencing improved exercise tolerance and reduced angina episodes. Additionally, the CardiALLO allogeneic cell therapy is advancing with no adverse events reported in its phase 1/2 study.
Financially, BioCardia’s net loss decreased for the quarter compared to the previous year, attributed to reduced compensation expenses. The company ended the quarter with a cash balance of $5.3 million, providing financial runway into the second quarter of 2026.
Looking ahead, BioCardia is poised for transformative growth with anticipated regulatory consultations and submissions, ongoing clinical trials, and strategic funding efforts. The company remains committed to advancing its therapeutic platforms and achieving key milestones in the coming quarters.